FIRST ONCOLYTIC VIRAL THERAPY APPROVED FOR HEAD AND NECK CANCER

A A

Shanghai Sunway Biotech Co. Ltd. announced today that the Chinese State Food and Drug Administration (SFDA) has approved H101, an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory Nasopharyngeal cancer, a type of head and neck cancer prevalent in China. This marks the first oncolytic viral therapy approved by any regulatory agency in the world.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1108957XSL_NEWSML_TO_NEWSML_WEB.xml)